Flowserve Corporation (NYSE: FLS) — A 235-Year-Old Flow-Control Cyclical Re-Rated on a Self-Help Margin Story, Priced for the 2030 Plan to Land

Standing note: the analysis in Sections 1–15 below is deliberately position-free — it contains no buy/sell recommendation and no price target, and discusses valuation only as embedded expectations and scenarios. The sole exception is the clearly-labeled Claude’s Take block immediately below, which is the author’s own subjective opinion.

⚡ Claude’s Take

The following is the author’s own subjective, independent opinion. It is general information, not investment advice. Everything from the Executive Summary onward (Sections 1–15) is position-free and carries no price target.

Verdict: HOLD — a genuinely improving, self-helped flow-control franchise whose easy re-rating is behind it, now priced for the 2030 margin plan to substantially deliver. Not a short (the turnaround is real and the aftermarket annuity is durable); not a buy here (you are paying ~17x forward adjusted earnings and near the richest EV/Sales in the company’s own history for a beta-1.4 cyclical earning roughly its cost of capital today). Fair-value accumulation zone ~$55–63 (≈14–16x the FY26 ~$4.10 adjusted-EPS guide / ≈12–13x EV/EBITDA — roughly the May-2026 low and the level at which the risk/reward turns favorable). Conviction: medium.

Flowserve is a real turnaround, not a mirage. Under CEO Scott Rowe the “Flowserve Business System” — 80/20 complexity reduction, operational excellence, and footprint/roofline consolidation — has driven thirteen consecutive quarters of adjusted gross-margin expansion (gross margin 27.5%→33.4% GAAP, adjusted gross margin now 37%+), lifted adjusted operating margin from single digits toward the mid-teens, and pushed adjusted EPS from $2.63 (2024) to $3.64 (2025) with a credible 2030 target of ~20% adjusted operating margin and double-digit EPS CAGR. The demand backdrop is favorable: a ~56%-of-bookings, high-margin aftermarket annuity off one of the largest installed bases in flow control, plus a genuine nuclear/power tailwind (~$400M of nuclear awards in 2025). This is a better-run company than the one that spent 2020–2022 earning a 3–5% ROIC.

But two things hold me to a HOLD. First, the market has already paid for the turnaround. The stock ran from ~$24 (2022) to a ~$92 all-time high (Feb-2026) — a near-4x — and even after a ~23% pullback to ~$70 it trades at the top of its own decade-long EV/Sales and EV/EBITDA ranges. GAAP ROIC is still only ~9–10% (roughly WACC); adjusted ROIC is a better ~12–13% but not moat-grade, and it sits at the low end of the flow/industrial peer set (below ITT’s ~15%, DOV’s ~10%, well below Graco/A.O. Smith). Second, this is a high-beta cyclical (β≈1.4) with real earnings quality caveats — a 38% GAAP-to-adjusted EPS wedge (Q4-2025 alone carried a $1.34/share asbestos-divestiture charge, plus recurring “one-time” 80/20 restructuring dressed as adjustments), oil-&-gas/chemical/Middle-East end-market exposure, and a backlog whose conversion is slowing as nuclear lengthens the cycle. And the people who know it best are not buying: into the ~4x re-rating insiders were 100% sellers — the CEO sold ~$15M (filed as discretionary, not a 10b5-1 plan) and no officer bought a single share — while the one large 2025 buyback was funded by a merger-break windfall and executed near the highs. Framing: a quality-improving industrial priced as a secular compounder, when it is still a cost-of-capital-return cyclical mid-way through a self-help story — the factor tape agrees (β 1.4, a strong 12-month run now stalling, ~16% drawdown last quarter, sitting on its 200-day). Bullish trigger: two-plus quarters of the 2030 algorithm showing up in consolidated numbers — adjusted operating margin marching through 16–17% with mid-single-digit organic bookings growth and adjusted ROIC clearly north of 13% — proving the margin plan compounds rather than plateaus. Bearish trigger: the cyclical end markets (oil & gas capex, chemicals, Middle East projects) roll over, organic growth stalls, and a rich ~17x forward multiple on a β-1.4 name de-rates toward its historical low-teens. Tag: “The pump finally works — but you’re buying it at the top of its own pressure curve.”

📈 Stock Price Action — Five-Year Event Map

Factual price history, not a recommendation. Price moves are Fact; attributed drivers are Interpretation.

Over five years Flowserve round-tripped from a COVID crash to a full re-rating and back through a sharp correction. In round numbers: a March-2020 low near $19, a range-bound $24–44 grind through 2021–2022 while returns languished, a margin-driven climb to $62 (2024) and $73 (Dec-2025), a blow-off all-time high of ~$92 (Feb-25-2026) on the FY2025 print and 2030 targets, then a ~30% correction to ~$64 (May-2026) on a sell-side downgrade, Middle-East disruption and a soft Q1 — leaving the stock at ~$70.48 today, roughly 23% below its February peak, at its 200-day moving average, with a 52-week range of $49–$92.

Cycle narrative. (1) The 2020 crash was macro/end-market, not company-specific — FLS is a levered play on oil-&-gas, chemical and power capex, all of which collapsed with COVID. (2) 2021–2022 was a lost middle: the stock went nowhere while Flowserve under-earned (ROIC 3–5%, a negative-FCF 2022 as working capital ballooned), the classic “structurally-OK business run below its potential.” (3–4) 2023–2024 was the re-rating leg — CEO Scott Rowe’s Flowserve Business System began converting into visible gross- and operating-margin expansion, and the multiple expanded with the earnings. (5) 2025 combined a tariff-shock April low with a powerful recovery to a record adjusted-EPS year, and included the abortive Chart Industries “merger of equals” (announced June, terminated July when Baker Hughes moved on Chart — Section 8). (6) The February-2026 blow-off to $92 was the market capitalizing the just-announced 2030 targets as if delivered. (7) The subsequent ~30% correction is the heart of today’s setup: a high-beta cyclical that got ahead of itself de-rated on a real Middle-East demand disruption, a soft North-American start to the year, and a prominent sell-side downgrade. (8) The stock has since stabilized on its 200-day. Every price move is a Fact; each attributed driver is Interpretation, cross-referenced to earnings dates, 8-K events, and the Q1-2026 call.

1. Executive Summary

Flowserve is a $4.7B-revenue, 235-year-old global leader in flow control — engineered and pre-configured pumps, mechanical seals, valves and automation, sold into oil & gas, chemical/pharmaceutical, power (including a fast-growing nuclear franchise), water and general industries. It operates two segments: the Flowserve Pump Division (FPD) — pumps, seals and the associated aftermarket — at roughly two-thirds of revenue, and the Flow Control Division (FCD) — valves, actuation and controls — at the balance. The economic heart of the business is the aftermarket: replacement parts, seals, repairs, upgrades and services sold off an enormous global installed base, representing ~56% of bookings and carrying structurally higher margins than original-equipment (OE) sales. This installed-base annuity, protected by qualification lock-in and the cost of unplanned downtime on mission-critical equipment, is the source of whatever moat Flowserve possesses.

The investment story is a self-help margin turnaround inside a cyclical, cost-of-capital-return business. Since 2018, and with real acceleration since 2023, CEO Scott Rowe has deployed the “Flowserve Business System” — an 80/20 complexity-reduction program (now in its third year), operational excellence, and aggressive footprint/roofline consolidation. The results are tangible and multi-year: GAAP gross margin has risen from 27.5% (2022) to 33.4% (2025), GAAP operating margin from a 4.9% trough to 11.0%, and management reports thirteen consecutive quarters of adjusted gross-margin expansion (adjusted gross margin now above 37%, adjusted operating margin in the mid-teens). Adjusted EPS reached $3.64 in 2025 (+38% YoY), and management has set 2030 targets of mid-single-digit organic sales CAGR, a ~20% adjusted operating margin, and a double-digit adjusted-EPS CAGR. The balance sheet is healthy (net leverage ~1.2x), free-cash conversion is guided at ≥90% of adjusted net income, and capital is being returned (~$365M of dividends and buybacks in 2025) and redeployed into bolt-on M&A (the $490M Trillium Flow Technologies Valves acquisition, signed mid-2026).

The tension is price versus the durability and quality of the inflection. Three facts frame it. First, returns are still modest. GAAP ROIC is ~9–10% — roughly the cost of capital — and even on adjusted operating income the figure is only ~12–13%, at the low end of the flow/industrial peer set (versus ITT ~15%, Dover ~10%, Graco ~18%, A.O. Smith ~27%). Second, earnings quality carries caveats. The gap between 2025 GAAP diluted EPS ($2.64) and adjusted EPS ($3.64) is a 38% wedge — driven in Q4 by a large asbestos-divestiture charge, and more chronically by intangible amortization and recurring 80/20 restructuring that is arguably a cost of doing business rather than a one-time item. Third, the price already reflects the good news. At ~$70.48 the stock trades at ~17x the FY2026 adjusted-EPS midpoint ($4.10), ~19x trailing adjusted, ~27x trailing GAAP, ~16x EV/EBITDA and ~2.1x EV/Sales — the last two near the richest levels in Flowserve’s own decade, on a business with a market beta of ~1.4 and meaningful cyclical and geopolitical exposure. The embedded expectation is that the 2030 self-help plan substantially delivers. It may — the operating record since 2023 earns management the benefit of the doubt — but the valuation leaves little margin of safety for the cyclicality, the Middle-East disruption, or a stall in the margin march. This memo takes no position; the labeled Claude’s Take above does.

2. Business Overview

Flowserve Corporation, headquartered in Irving (Dallas), Texas and tracing its corporate lineage to 1790, is one of the world’s largest providers of flow-control products and services — the pumps, seals, valves and automation that move, control and contain fluids in heavy-process industries. FY2025 revenue was $4.729 billion, up 3.8% year-over-year, generated across two operating segments and a global manufacturing and service footprint spanning the Americas, Europe, the Middle East, Africa and Asia-Pacific.

Flowserve Pump Division (FPD) — roughly two-thirds of revenue. FPD designs, manufactures and services custom-engineered and pre-configured pumps and pump systems, mechanical seals, auxiliary sealing systems, and the associated aftermarket (installation, commissioning, spare parts, repairs, advanced diagnostics, re-rate/upgrade solutions, retrofits and asset-management services). It also makes gas-lubricated mechanical seals for high-speed compressors in gas pipelines and oil-&-gas production/processing. FPD’s economic core is the razor/razor-blade dynamic: an installed pump or seal generates decades of high-margin replacement-part and service revenue. In Q1-2026 FPD ran an adjusted operating margin of ~19%.

Flow Control Division (FCD) — roughly one-third of revenue. FCD provides engineered and industrial valves and automation — isolation and control valves, actuation, controls and related equipment — plus the corresponding maintenance, repair, installation, commissioning, retrofit and field-machining services. FCD’s products control, direct and manage the flow of liquids, gases and multi-phase fluids. FCD has been the larger 80/20 margin-improvement opportunity (it started the program later); Q1-2026 adjusted operating margin reached ~15.9%, up 370bp year-over-year, and the Trillium Valves acquisition is an FCD bolt-on.

Revenue model — OE plus a large aftermarket annuity. Flowserve sells through direct sales, distributors and representatives. Bookings split into original equipment (OE) — new pumps, valves and projects, cyclical and tied to customer capital cycles — and aftermarket (AM) — parts, seals, repairs and services, recurring and tied to the installed base’s operation and maintenance. In 2025, aftermarket bookings were $2,644.5M (56% of total bookings) and grew 9.2%, marking eight consecutive quarters above $600M; OE bookings were $2,068.5M and declined 7.6% off a strong prior-year comparison. This mix is the single most important quality feature of the business: the aftermarket is stickier, higher-margin, and prices with (rather than against) inflation, while OE seeds the future aftermarket. Year-end backlog was $2,867.8M (+2.8%), of which management expects ~76% to ship within twelve months — a lower conversion rate than the historical mid/high-80s because the rising nuclear mix carries longer lead times.

End markets. Flowserve’s primary end markets are oil & gas (upstream, midstream, refining/downstream), chemicals and pharmaceuticals, power generation (including a strategically emphasized nuclear franchise — traditional reactors, life-extensions/re-rates of the existing fleet, and small modular reactors), and water management, plus general industries (mining and ore processing, pulp and paper, food and beverage). This end-market mix makes Flowserve a levered play on global energy, chemical and power capital-expenditure and maintenance cycles — the source of both its cyclicality and its multi-decade installed-base annuity.

Verdict: A focused, scaled, globally-diversified flow-control franchise with a genuinely valuable recurring-aftermarket core and a cyclical OE layer. It is a good — not great — business model: the aftermarket annuity and installed base are real assets, but the OE layer is cyclical and the end markets (energy, chemicals) are capital-intensive price-cyclicals. The quality of the model is rising as aftermarket mix and margins improve.

3. Industry Dynamics

The global flow-control industry — industrial pumps, valves, seals and actuation — is a large, mature, fragmented, and structurally decent (not great) set of markets. The industrial-pump market alone is on the order of $70B+ globally, growing low-to-mid-single digits; the industrial-valve and mechanical-seal markets add tens of billions more. No single player dominates: the field comprises diversified industrials (Flowserve, ITT/Goulds, Xylem, Dover, Emerson, Baker Hughes), large privately-held specialists (Sulzer, KSB, Grundfos, John Crane/Smiths, Weir), and thousands of regional OEMs.

Where the profit pool sits — the aftermarket. The defining structural feature of flow control is the bifurcation between low-margin, cyclical, competitively-bid original equipment and high-margin, recurring, semi-captive aftermarket. New pumps and valves are often sold at thin margins to win the installed position; the economics are made over the following twenty-plus years selling seals, impellers, parts, rebuilds and upgrades into an installed base where the cost of unplanned downtime dwarfs the cost of the OEM part. This is the same razor/razor-blade structure the author has documented at ITT (Goulds pumps, ~40% aftermarket, 21.7% segment margin) and Pentair (pool aftermarket). It is the reason a scaled installed base is the industry’s most valuable asset and the anchor of pricing power.

Competitive intensity — high in OE, muted in aftermarket. OE is genuinely competitive: buyers are sophisticated engineering/procurement firms and plant operators who tender projects and exert pricing leverage, and there are many capable global and regional bidders. The aftermarket is far less contestable — once a Flowserve pump is specified into a refinery or a Flowserve valve into a chemical plant, the metallurgy, dimensions, spares, and maintenance procedures are built around it, and requalifying an alternative is slow, costly and risky. This is a local, installed-base economies-of-scale-plus-captivity advantage in Greenwald’s taxonomy, operating at the plant level.

Regulatory and structural factors. Flow control benefits from several durable demand drivers: (i) energy security and reinvestment — post-2022 the world is rebuilding and diversifying energy infrastructure, and the Middle-East disruption of 2025–2026 is, perversely, a medium-term tailwind (reconstruction and capacity additions off Flowserve’s enormous regional installed base); (ii) the nuclear renaissance — life-extensions and re-rates of the existing fleet, new traditional reactors in Europe/Asia/US, and eventually small modular reactors, all of which are pump-, valve- and seal-intensive with high qualification barriers; (iii) electrification and power-demand growth (data centers, industrial load); (iv) decarbonization/LNG, hydrogen, carbon capture; and (v) chemical reinvestment and water infrastructure. These are real, multi-year, and largely policy-supported.

The Marathon capital-cycle read. Flow control is a disciplined-supply-side industry at the aftermarket level — small, qualification-gated niches keep new capital out, which is why installed-base returns are high — but the OE layer is a classic capital-cyclical, where energy/chemical capex booms pull in capacity and busts wring it out. Flowserve’s own history is a textbook capital cycle on the OE side: the 2020–2022 energy-capex bust crushed its returns (ROIC 3–5%), and the 2023–2026 recovery has lifted them. Critically, management has (per the transcripts) added capacity against secured awards and reduced footprint via 80/20 rather than chasing the cycle — the disciplined side of the capital cycle.

Verdict: a structurally decent industry — good at the aftermarket layer, cyclical and competitive at the OE layer, with genuine multi-year secular demand drivers (energy security, nuclear, power, decarbonization). It is not a great industry (mature, fragmented, capital-intensive, cyclical), but it is a durable one with a high-quality recurring profit pool for the scaled incumbents that own the installed base.

4. Competitive Position

Name the moat honestly: Flowserve’s advantage is a moderate installed-base-aftermarket moat, not a wide one. Flowserve is one of the two or three largest players in global flow control, with one of the industry’s largest installed bases of pumps, seals and valves — “probably more pumps than any other provider in the world,” in the CEO’s words about the Middle East alone. That installed base is the asset. Every pump, seal and valve in the field is a multi-decade annuity of parts, repairs and upgrades, protected by three reinforcing barriers:

1. Switching costs / qualification lock-in. Mission-critical flow equipment in refineries, chemical plants, nuclear stations and pipelines is specified, installed, and maintained around a particular OEM’s dimensions, metallurgy and spares. Switching brands means re-engineering the install, requalifying materials for the process chemistry, retraining maintenance, and re-stocking spares — for equipment that works. The cost of unplanned downtime (often worth far more per hour than any part) makes plants overwhelmingly buy the OEM part or an OEM-authorized rebuild. This is the core of Flowserve’s aftermarket pricing power.

2. Scale and breadth of the installed base and service network. Flowserve’s ~56%-of-bookings aftermarket, its global Quick Response Center (QRC) and service footprint, and its breadth across pumps, seals and valves let it capture more of a customer’s flow-control wallet and respond faster than sub-scale rivals — a local economies-of-scale advantage in each region/plant it densely serves.

3. Engineering reputation and specification. In high-consequence applications (nuclear, high-pressure/high-temperature refining, pipelines), customers specify by name and value a multi-decade track record and reliability data that new entrants cannot replicate quickly — an intangible-plus-switching-cost barrier, especially strong in nuclear where Flowserve emphasizes an “unbelievable installed base and entitlement.”

The financial test — where the moat narrative must be disciplined. A moat must show up in returns, and here Flowserve’s evidence is improving but not yet conclusive. For a decade the company earned a 3–8% ROIC — below its cost of capital — despite owning this installed base, because it ran the business inefficiently (excess complexity, poor pricing discipline, a bloated footprint). That is the tell that Flowserve historically had a moat but dissipated the rents through poor execution. The 80/20/Flowserve Business System turnaround is, in effect, the company finally monetizing a moat it always had: adjusted operating margin toward the mid-teens and adjusted ROIC toward ~12–13% is the moat showing up at last. But GAAP ROIC of ~9–10% is still only cost-of-capital, and the returns sit at the low end of the flow/industrial peer set — below ITT (~15%), Graco (~18%), A.O. Smith (~27%), and even Dover (~10%). The moat is real but moderate, and the excess returns are still being built, not yet banked.

Direct competitor comparison. Against ITT (Goulds) — the cleanest comp — Flowserve is larger and broader (pumps + seals + valves vs. Goulds’ process-pump focus) but lower-returning (ITT earns mid-teens ROIC and ~18% adjusted operating margins today; Flowserve is climbing toward those levels but is a couple of years behind). Against Xylem, Flowserve is more energy/chemical-weighted and less water/utility-weighted; both earn sub-double-digit-to-low-double-digit ROIC. Against Sulzer, KSB and John Crane (Smiths), Flowserve competes head-to-head in pumps and seals and holds a leading scale position. Against Emerson and Baker Hughes in valves/automation, Flowserve is a focused specialist rather than a scaled automation platform. The Greenwald share-stability test is roughly satisfied — Flowserve’s share of its core pump/seal/valve niches has been stable for years — but it fails the dominant-scale test (it is one of several large players, not a monopolist), which is why returns are mid-teens-at-best rather than the 25%+ of a true scale-plus-captivity franchise.

Verdict: a genuine but moderate installed-base/aftermarket moat, historically under-earned and now being monetized — durable enough to protect the aftermarket annuity, not wide enough to justify a premium secular-compounder multiple on its own. The competitive question for the thesis is not whether the moat exists (it does) but whether management can keep converting it into ITT-like mid-teens returns; the record since 2023 says probably, but it is not yet done.

5. Growth History and Forward Opportunities

Historical growth — cyclical, with a recent step-up. Flowserve’s revenue is fundamentally cyclical and tied to energy/chemical/power capex. Revenue was $3.73B (2020), dipped to $3.54B (2021) and $3.62B (2022) through the post-COVID energy trough, then inflected sharply: $4.32B (2023, +19%), $4.56B (2024, +5.5%), and $4.73B (2025, +3.8%). The 2023 jump was the energy-capex recovery plus backlog conversion; 2024–2025 growth was more measured and increasingly aftermarket- and margin-led. Importantly, much of the recent earnings growth has come from margin, not volume — the 80/20 program deliberately walks away from low-margin revenue (a headwind to the top line), so reported organic growth understates the quality improvement.

Aftermarket is the growth engine that matters. Aftermarket bookings grew 9.2% in 2025 to $2.64B and have been above $600M for eight straight quarters — a durable, high-margin, installed-base-driven stream that Flowserve is deliberately expanding by raising “capture rates” on its own installed base (winning the parts/service business that historically leaked to third parties). This is the highest-quality growth in the company and the most defensible.

Forward opportunities. Management’s 12-month project funnel is, per the Q1-2026 call, “up year-on-year and sequentially, across all end markets.” The specific growth vectors are:

• Nuclear/power — the standout. ~$400M of nuclear awards in 2025 and a ~$100M/quarter run-rate, spanning existing-fleet re-rates and life-extensions (steady), new traditional reactors in Europe (management is “optimistic” on European reactor awards within 2026) and the US/Asia, and early SMR engineering work (real revenue “a couple of years away”). Nuclear is pump-, valve- and seal-intensive with high qualification barriers — a genuine multi-year tailwind.
• Middle-East reconstruction — perversely, the 2025–2026 conflict that hurt near-term bookings sets up a medium-term rebuild opportunity off Flowserve’s massive regional installed base, plus energy-security-driven capacity additions.
• Aftermarket capture-rate expansion — the most controllable and highest-quality lever.
• General industries — mining, pharma, food & beverage, water — a diversification away from oil & gas.
• M&A — bolt-ons like Trillium Valves ($490M) add scope and aftermarket.
• Chemical — the lowest-growth end market, expected to “modestly improve.”

Near-term reality check. 2026 is a transition year: FY2026 organic guidance was cut at Q1 (from +1/+3% to −1/+2%) on the Middle-East disruption and a soft North-American start to the year, with total sales growth of 3–6% carried largely by acquisitions (~+300bp) and FX (~+100bp). Management expects a back-half-weighted recovery in OE bookings and holds its adjusted-EPS guide via margin.

Verdict: a mix of high-quality (aftermarket capture, nuclear) and cyclical/lower-quality (OE project timing, FX/M&A-carried) growth. The durable, defensible growth is the aftermarket annuity and the nuclear franchise; the reported top line is cyclical and, near-term, soft. This is decent growth of improving quality — mid-single-digit organic at best, dressed up by M&A and margin — not a secular-growth story.

6. Financial Quality

The core story is margin, and the margin story is real. Over 2020–2025 Flowserve lifted GAAP gross margin from ~29–30% to 33.4% and GAAP operating margin from the mid-single-digits (a 4.9% trough in 2022) to 11.0%; on an adjusted basis, management reports thirteen consecutive quarters of gross-margin expansion, an adjusted gross margin above 37%, and an adjusted operating margin in the mid-teens (15.1% in Q1-2026). This is a durable, program-driven transformation (80/20 SKU/complexity reduction, operational excellence, footprint/roofline consolidation, pricing discipline), not a one-quarter cyclical pop — and the incremental operating margins have been strong (36.8% incremental in 2025).

Earnings and the GAAP-to-adjusted wedge (quality-of-earnings flag). GAAP diluted EPS rose from $1.44 (2022) to $2.14 (2024) to $2.64 (2025); adjusted EPS rose from $2.63 (2024) to $3.64 (2025). The 38% wedge between 2025 GAAP and adjusted EPS is a caveat that must be scored. In Q4-2025 alone, adjusted items totaled $1.34/share, dominated by a one-time asbestos-divestiture charge (Flowserve moved to shed its legacy asbestos liability — a genuine one-time, and arguably a positive de-risking) — Q4 GAAP EPS was ($0.23) versus adjusted $1.11. Across the year the wedge also includes intangible amortization (a real, if non-cash, cost of the M&A model) and recurring realignment/footprint restructuring — the latter is the one to watch, because the 80/20 footprint program is ongoing “every year,” which makes some of the “one-time” restructuring effectively a recurring cost of the operating model. Adjusted EPS is therefore a reasonable proxy for run-rate earnings power but is flattered relative to a stricter definition; the honest run-rate is somewhere between GAAP $2.64 and adjusted $3.64, probably closer to the adjusted figure ex-asbestos but net of ongoing restructuring — call it ~$3.10–3.40.

Returns on capital — the honest weak spot. ROIC.ai computes ROIC of 4.7% (2020) → 8.7% (2023) → 10.0% (2024) → 9.4% (2025) on GAAP operating income, and ROE of 7.9% (2025). Against an estimated WACC of ~9% (beta ~1.4, cost of equity ~10–11%, ~15% debt weight), GAAP returns are roughly at the cost of capital. On adjusted operating income (mid-teens margin), adjusted ROIC is a better ~12–13% — a genuine spread over WACC, and the number the bull case rests on. Either way, Flowserve sits at the low end of its peer set on returns (ITT ~15%, Graco ~18%, A.O. Smith ~27%, Dover ~10%, Xylem ~8%, IDEX ~9%). The 2030 target of ~20% adjusted operating margin implies adjusted ROIC pushing toward the mid-teens — i.e., the whole bull case is a returns-improvement story, and it is not yet finished.

Free cash flow. Cash from operations was $506M (2025), $425M (2024), $326M (2023) and negative $40M (2022, a working-capital blow-out as inventory and receivables surged into the recovery). Capex is modest (~$90–100M/year), so free cash flow is roughly $400–500M and management guides FY2026 conversion to ≥90% of adjusted net income. FCF/share is ~$3.20–3.89; the 2022 negative-FCF year is a reminder that this is a working-capital-intensive, cyclical business whose cash generation is lumpy and can invert in a fast recovery.

Balance sheet. Solid but not fortress. Cash $760M, total debt $1.76B, net debt $815M, net debt/EBITDA ~1.3x (management: net leverage 1.2x), EBITDA/interest ~7.9x. In April 2026 Flowserve extended its credit facility five years and increased revolver capacity. Tangible book is minimal — goodwill ($1.39B) plus intangibles ($0.20B) mean tangible book value/share is only ~$5.11 (P/TBV ~13.6x), so the business must be judged on cash and earnings, not book. There is a minority interest (~$63M) reflecting joint ventures (including in the Middle East), which slightly complicates the equity picture.

Data-integrity note: The AZI valuation feed reports a book value per share of $17.20 (implying P/B ~4.1x, a 95th-percentile “richest-ever” reading). This is a garbled figure — Flowserve’s actual common book value per share is ~$34.48 (P/B ~2.0x), consistent with ~$2.19B common equity and a 7.9% ROE on $346M net income. The correct P/B (~2.0x) is near the high end of Flowserve’s own history but is not the 4.1x the raw feed shows. This report uses the reconciled ~2.0x figure.

Verdict: economics are improving with scale and self-help — margins and adjusted returns are on a genuine multi-year upswing — but the business still earns only roughly its cost of capital on a GAAP basis, converts cash lumpily, and carries a meaningful GAAP-to-adjusted earnings wedge. The direction is clearly positive; the absolute level of returns is still mid-pack-to-low for the peer group, and the quality of the “adjusted” earnings deserves a skeptical eye.

7. Capital Allocation

Flowserve’s capital allocation over 2020–2025 has been disciplined and conservative, but modest in return of capital until a 2025 windfall-funded step-up, with a recent pivot toward bolt-on M&A in power and nuclear. The verdict is improving and now well-incentivized, with one important caveat about the reliance on adjusted metrics.

Dividends — flat. The declared dividend was $0.80/share (2022–2023), raised modestly to $0.84 (2024–2025) — essentially flat for the entire window, ~$105–110M/year in cash, a ~28% payout of GAAP EPS, and a ~1.2% yield. There was no dividend cut in 2020–2025 (Flowserve’s well-known dividend cut predates this window and is outside the mirrored corpus). This is deliberately not a dividend-growth story; the flat payout preserves cash for reinvestment and buybacks.

Buybacks — dormant, then a 2025 spike funded by a windfall. Repurchases were negligible ($32M in 2020, $17.5M in 2021) and zero in 2022–2023, then a token $20M (2024) and a large $254.9M in 2025. The timing is telling: the 2025 buyback surge was substantially funded by the $266M cash termination fee Flowserve collected when the Chart merger fell through (see Section 8). Total 2025 shareholder returns were ~$365M (buybacks + dividends). This is opportunistic rather than programmatic — the buyback turned on only when a windfall arrived and the stock was, in hindsight, near its highs (a mild negative on execution: repurchasing $255M of stock in a year the shares hit ~$92 is buying high).

M&A — a bolt-on pivot into power/nuclear. After the abortive transformational Chart merger, Flowserve has redeployed into disciplined, on-strategy bolt-ons: MOGAS Industries (~$306M cash, 2024 — severe-service/high-pressure valves for mining and oil & gas), Greenray Turbine Solutions (~$66M, 2025), and the Trillium Flow Technologies Valves Division ($490M all-cash, closed June-30-2026 — mission-critical nuclear/power valves and actuation, ~$200M annualized revenue at high-teens EBITDA margins). The Trillium price implies ~2.45x revenue and ~13–14x pre-synergy EBITDA — a full multiple for a bolt-on, betting on 80/20 margin uplift and nuclear/power demand to make it work. These deals are strategically coherent (they deepen the higher-margin valve/aftermarket and power/nuclear franchises) but are being bought at industrial-M&A prices, so accretion depends on execution, not on cheap purchase multiples.

Balance sheet — conservative, ample capacity. Net debt has been roughly flat at ~$0.8B (net leverage ~1.0–1.3x EBITDA) through the entire window; the $490M all-cash Trillium deal was easily fundable from ~$760M of cash, and the credit facility was extended and upsized in April 2026. Flowserve has meaningful additional M&A/buyback capacity.

Incentive alignment — genuinely tied to the margin/ROIC thesis (the strongest positive here). The 2026 proxy shows management is paid on precisely the metrics that matter to this thesis. The annual bonus weights Adjusted Operating Income 50% (margin), Customer Bookings 30% (growth), and Adjusted Primary Working Capital 20% (cash). The long-term PSU plan weights ROIC 50% and Free-Cash-Flow conversion 50%, with a relative-TSR modifier (±15%). Only 30% of the bonus and none of the LTIP is a pure growth metric; half the LTIP is explicitly return-on-capital — exactly the alignment is what quality investors look for and rarely find (contrast Xylem and IDEX, whose plans carry no return-on-capital metric). CEO Scott Rowe earned $10.9M (2025); ownership guidelines are robust (CEO 6× salary); say-on-pay passed with >97% support. The one caveat: the incentive metrics are all “adjusted”/non-GAAP, and payouts have run hot (ROIC PSUs paid ~192–215% of target for 2023–2025), so the alignment rewards the adjusted margin/ROIC story — the same figures whose quality Section 6 flagged.

Insider behavior — the sobering counter-signal. Into a ~2.3x re-rating (~$30 in 2022 to a ~$92 peak in 2026), insider activity was 100% distribution by operators. Across January-2025 to July-2026, officers made zero discretionary open-market purchases; the CEO sold ~213,000 shares for ~$15.0M (his largest tranche filed as discretionary, not under a 10b5-1 plan), and the CFO sold ~$3.3M. The only open-market buys were two token director qualifying purchases (~$0.23M combined, near the May-2026 lows). Management is well-aligned on paper (via PSUs) but is not putting new personal money in at these prices — a classic “no conviction in further upside from here” tell that reinforces the valuation caution, even as it says nothing bad about the business.

Verdict: capital allocation is disciplined, conservatively levered, and — importantly — incentivized on margin and ROIC rather than empire-building; but the return of capital is modest and opportunistic (a windfall-funded 2025 buyback near the highs), the M&A is being done at full prices, and insiders are net sellers with zero conviction buying. On balance, competent and improving, not a standout — and the incentive alignment is the best feature.

8. Changes and Headwinds — Last Two Years

The last two years have been eventful, dominated by a transformational merger that collapsed into a windfall, a pivot to bolt-on M&A, a real geopolitical disruption, and the formalization of the margin turnaround into 2030 targets.

The Chart Industries “merger of equals” — announced, then collapsed (net positive for FLS). On June 3, 2025, Flowserve agreed to an all-stock merger of equals with Chart Industries (NYSE: GTLS) — each Chart share to convert into 3.165 Flowserve shares, leaving Chart holders with ~53.5% and Flowserve holders ~46.5% of a combined ~$19B-EV, ~$8.8B-revenue flow-and-process company (with ~42% aftermarket), to be led by Scott Rowe as CEO. The strategic logic was scale, ~$300M of cost synergies, and a “clean energy / process” positioning. It terminated on July 28, 2025 — publicly, because Chart accepted a superior ~$13.6B acquisition offer from Baker Hughes. Critically, Flowserve was the net beneficiary of the break: it collected $266M in cash ($250M Chart termination fee + $16M expense reimbursement), which substantially funded the 2025 buyback. The episode reveals management’s willingness to pursue transformational scale, but the outcome left Flowserve standalone, cash-richer, and refocused on organic execution plus bolt-ons — arguably a better outcome than integrating a large, differently-cultured merger at a ~2.0x-levered close.

Bolt-on M&A pivot. Post-Chart, Flowserve executed the MOGAS (2024, $306M), Greenray (2025, $66M) and Trillium Valves (2026, $490M) acquisitions — deepening severe-service valves and the nuclear/power franchise (see Section 7). Trillium closed June-30-2026 and is the largest, at a full ~13–14x EBITDA.

The 2025–2026 Middle-East disruption — the live headwind. Regional conflict (a renewed Middle-East flare-up into 2026) disrupted Flowserve’s operations around its ~800 in-region associates and large installed base, cutting Q1-2026 bookings by ~$50M and sales by ~200bp, and prompting a downward revision to FY2026 organic-growth guidance (from +1/+3% to −1/+2%). Management frames it as two-sided: a near-term drag, but a medium-term tailwind from reconstruction and energy-security-driven capacity additions off Flowserve’s enormous regional footprint. Guidance assumes no material escalation.

The Q4-2025 asbestos divestiture. Flowserve moved to shed its legacy asbestos liability in Q4-2025, taking a large one-time charge (the bulk of the $1.34/share of Q4 adjusted items) that pushed Q4 GAAP EPS to ($0.23). This is a genuine de-risking — removing a long-tail legacy liability — at a one-time cash/accounting cost, and it is the main reason the 2025 GAAP-to-adjusted EPS wedge is so wide.

2030 targets formalized. In February 2026 Flowserve set explicit 2030 financial targets — mid-single-digit organic sales CAGR, ~20% adjusted operating margin, and double-digit adjusted-EPS CAGR (2025–2030) — converting the self-help narrative into a numeric bogey the market has largely capitalized.

Leadership. Matt Copper was promoted to lead the FPD division (March-2026); CFO Amy Schwetz and CEO Scott Rowe remain in place — continuity on the turnaround.

Sell-side. TD Cowen downgraded Flowserve to Hold with a $70 price target (June-24-2026), reflecting the “fairly valued after the run” consensus that accompanied the ~30% Feb→May correction.

Verdict: on balance these developments strengthen the balance sheet and strategic focus (a windfall from the failed merger, disciplined bolt-ons, a de-risked asbestos liability, formal 2030 targets) while introducing a real near-term cyclical/geopolitical headwind (Middle East) and confirming that the stock is now fairly valued in the market’s eyes. The thesis is intact but more fully priced than a year ago.

9. Risk Analysis (Risk Matrix)

Overall: The dominant risks are cyclicality and margin-plan execution meeting a rich valuation — the combination that makes a β-1.4 name at ~17x forward vulnerable. Geopolitics (Middle East) is high-likelihood but two-sided and medium-impact. There is no catastrophic-loss risk; the balance sheet is sound.

10. Valuation Discussion (Embedded Expectations)

No price target; no recommendation. Valuation is discussed only as embedded expectations and scenarios.

Where the multiple sits. At $70.48 (market cap ~$8.9–9.0B, EV ~$10.1B), Flowserve trades at:

• ~27x trailing GAAP EPS ($2.64) — distorted upward by the asbestos charge;
• ~19x trailing adjusted EPS ($3.64);
• ~17x the FY2026 adjusted-EPS guide midpoint ($4.10) — the cleanest forward figure;
• ~16.4x EV/EBITDA (2025 reported EBITDA $615M) — versus a 5-year average of ~14x and a high of ~17.5x;
• ~2.1x EV/Sales — versus a 5-year average of ~1.75x and a high of ~2.28x (i.e., near the richest in the company’s own decade);
• ~4.5% free-cash-flow yield (FCF ~$400–500M on ~$9B equity).

On the AZI own-history percentiles, the P/S sits in the ~95th percentile and the composite in the ~79th (the P/B percentile is unreliable — see Section 6 data note; the P/E percentile is muddied by the GAAP asbestos distortion). Cross-sectionally, ~17x forward adjusted is a discount to the closest quality comps (ITT ~25x, Dover ~22x forward) but on lower current returns (ROIC ~9–13% vs. ITT’s ~15%), so the discount is warranted rather than a clear bargain.

Embedded-expectations / reverse-DCF read. At an EV of ~$10.1B against current free cash flow of ~$450–500M, a simple perpetuity at a ~9% WACC and ~3% terminal growth implies the market is capitalizing something close to current FCF growing modestly to ~$580–600M and then compounding at ~3%. In plainer terms, the price embeds the successful, on-schedule delivery of the 2030 self-help plan — mid-single-digit organic growth plus margin expansion to ~20% adjusted operating margin, which would take revenue toward ~$6.3B, adjusted operating income toward ~$1.25B, adjusted EPS toward ~$7.5–7.7 (a double-digit CAGR off $3.64), and free cash flow toward ~$700M by 2030. At today’s price that is ~9x 2030 adjusted EPS — undemanding if delivered, but the whole return depends on delivery.

Scenario analysis (illustrative, not price targets):

• Bull: 2030 plan lands — ~$6.3B revenue, ~20% adj margin, ~$7.5 adj EPS, ~$700M FCF, adjusted ROIC into the mid-teens. A quality-industrial multiple (18–20x) on ~$7.5 would be a materially higher enterprise value; the re-rating would be earnings-driven, since the multiple is already full.
• Base: margin march continues but slower, cyclicality caps organic growth, adjusted EPS reaches ~$5.5–6.0 by 2028–2029; the stock compounds with earnings at a roughly flat multiple — a mid-single-digit to low-double-digit total return (FCF yield + EPS growth − multiple drift).
• Bear: energy/chemical capex rolls over, organic growth stalls, the margin plan plateaus in the mid-teens, and a β-1.4 name at ~17x forward de-rates toward its historical low-teens P/E and ~12–13x EV/EBITDA — a meaningful drawdown even on flat earnings, as the Feb→May-2026 −30% move previewed.

What the market is underwriting correctly vs. incorrectly. Correctly: the aftermarket annuity’s durability, the reality of the margin program, and the nuclear/energy-security tailwind. Potentially incorrectly: extrapolating a cyclical-plus-self-help margin recovery as a secular-compounder trajectory, and paying a near-record EV/Sales for a business that still earns roughly its cost of capital on GAAP and sits at the low end of the peer return set. The valuation prices success; it does not price the cyclicality or an execution stall.

11. Variant Perception

Consensus view. Sell-side and market consensus treats Flowserve as a successful, mid-cycle industrial turnaround — a self-help margin compounder with a credible 2030 plan, a favorable nuclear/energy tailwind, and a reasonable ~17x forward multiple. The June-2026 TD Cowen downgrade to Hold ($70 PT) signals that even the constructive camp now sees the stock as fairly valued after the run.

Strongest bull case. Flowserve is early in a multi-year returns transformation: the same installed-base moat that produced only 3–5% ROIC under poor management can, under the Flowserve Business System, produce ITT-like mid-teens returns — and the market is paying only ~17x forward and ~9x 2030 EPS for that trajectory, a discount to higher-quality flow peers. The aftermarket annuity (56% of bookings, +9%/year), the nuclear franchise (~$400M/year of awards, high barriers), Middle-East reconstruction optionality, and disciplined bolt-on M&A (Trillium) compound the story. If the 2030 targets land, earnings roughly double and the stock re-rates on earnings, not multiple.

Strongest bear case. This is a β-1.4 energy/chemical cyclical at the top of its own valuation range, earning roughly its cost of capital, with a 38% GAAP-to-adjusted earnings wedge and a backlog softening at the margin. The margin gains from 80/20 are real but finite — they plateau — and the 2030 plan requires both continued margin expansion and mid-single-digit organic growth that the cyclical, competitive OE market may not deliver. The Middle-East disruption, the soft North-American start to 2026, and the −30% Feb→May correction are the tape telling you the extrapolation is fragile. At ~17x forward on peak-ish margins, the downside is mostly multiple, with little valuation cushion.

The 3–5 assumptions that matter most:

1. Durability of the margin march — does adjusted operating margin actually reach ~20% by 2030, or plateau in the mid-teens? (The single biggest swing factor.)
2. Organic growth — can Flowserve grow mid-single-digits organically through a cycle, or is the top line structurally low-single-digit (with growth bought via M&A)?
3. Cyclical timing — where are oil & gas / chemical / power capex in their cycle, and does the nuclear/energy-security tailwind offset a broader capex rollover?
4. Earnings quality — how much of “adjusted” EPS is genuine run-rate versus recurring restructuring dressed as one-time?
5. Capital allocation — does management redeploy free cash and M&A capacity accretively (bolt-ons like Trillium) after the abortive Chart merger, without a value-destructive large deal?

Falsification tests. Bull falsified if two-plus quarters show adjusted operating margin stalling in the mid-teens with organic bookings growth below low-single-digits — the plateau. Bear falsified if adjusted operating margin marches through 16–17% with mid-single-digit organic bookings growth and adjusted ROIC clearly above 13% — proving the plan compounds.

Factor-positioning read (input, not a call). The FactorsToday model reads Flowserve as a high-beta (β≈1.4) cyclical with a strong trailing-12-month return (+32% annualized) that has stalled hard — the last quarter was roughly −16% (−50% annualized), the stock sits ~23% off its relative-strength peak and on its 200-day moving average, and its factor-similar peers (EnerSys, WESCO, Emerson, Terex, ITT) are cyclical industrials, not secular compounders. This is the empirical signature of a crowded momentum-cyclical trade that has rolled over, consistent with the bear’s “extrapolation is fragile” framing and with a consensus that may be offsides on the secular-compounder narrative. It is evidence for the variant, not a price prediction.

12. Fact vs. Interpretation Table

| # | Statement | Fact / Interpretation | Basis | | : | :------------------------------------------------------------------------------------------------ | :-------------------- | :-------------------------------------------------------------------------- | | 1 | FY2025 revenue was $4.729B; adjusted EPS $3.64 vs GAAP diluted $2.64 | Fact | FY2025 press release (8-K, 2026-02-05); ROIC.ai income statement | | 2 | Thirteen consecutive quarters of adjusted gross-margin expansion; adj GM >37% (Q1-2026) | Fact | Q1-2026 earnings call (2026-04-30, CFO Schwetz) | | 3 | Aftermarket = 56% of 2025 bookings ($2.64B, +9.2%) | Fact | FY2025 press release | | 4 | GAAP ROIC ~9–10% (2024–2025); adjusted ROIC ~12–13% | Fact / Interp | ROIC.ai (GAAP); adjusted is Claude’s estimate on adj op income | | 5 | Flowserve earns roughly its cost of capital on GAAP | Interpretation | ROIC ~9.4% vs. WACC est. ~9% | | 6 | The 80/20/Flowserve Business System is a genuine, durable margin transformation | Interpretation | Multi-year margin trend + management commentary (validated vs. filings) | | 7 | The moat is a moderate installed-base/aftermarket advantage, not a wide one | Interpretation | Peer-relative returns; Greenwald tests | | 8 | The 38% GAAP-to-adjusted wedge includes recurring restructuring dressed as one-time | Interpretation | Cash-flow/press-release adjustments; 80/20 “every year” (transcript) | | 9 | The stock trades near the richest EV/Sales (~2.1x) in its own decade | Fact | ROIC.ai valuation multiples (5-yr history) | | 10| The price embeds successful delivery of the 2030 plan | Interpretation | Reverse-DCF / embedded-expectations analysis | | 11| Net leverage ~1.2x; FCF conversion guided ≥90% | Fact | Q1-2026 call; ROIC.ai credit ratios | | 12| The Middle-East disruption is two-sided (near-term drag, medium-term rebuild upside) | Interpretation | Q1-2026 call (management) |

13. Open Questions

1. How much of the 80/20 margin benefit is left, and does adjusted operating margin actually reach ~20% by 2030 — or plateau in the mid-teens?
2. What is the true run-rate earnings power net of recurring restructuring — i.e., how much of the $3.64 adjusted EPS survives a stricter definition (my estimate ~$3.10–3.40)?
3. Where are oil & gas / chemical / power capex in the cycle, and can nuclear/energy-security demand offset a broader capex rollover?
4. Capital-allocation intent post-Chart — after the abortive merger of equals (and the $266M windfall), is management committed to disciplined bolt-ons and buybacks, or is another large transformational deal on the table?
5. Nuclear backlog realization — how much of the lengthening nuclear backlog converts to revenue on schedule vs. slips?
6. Why zero officer conviction buying? Management is well-aligned via PSUs and paid on ROIC/margin, yet no officer has bought a single share in the open market through the re-rating (Section 7). Is that simply “fully valued,” or a signal about their own confidence in the 2030 targets they set?
7. Trillium integration — does the $490M (~13–14x EBITDA) deal deliver the 80/20 margin uplift and nuclear/power synergy that justify the full price?

14. What Must Be True

For the bull case (owning here works out):

• Adjusted operating margin continues its march to ~18–20% by 2030 (the margin plan compounds rather than plateaus).
• Flowserve grows mid-single-digits organically through the cycle, with aftermarket capture and nuclear offsetting OE cyclicality.
• Adjusted ROIC rises clearly through 13% toward the mid-teens — the moat finally banking excess returns.
• Capital allocation stays disciplined (accretive bolt-ons + buybacks, no value-destructive large deal).
• Falsification test: two consecutive quarters of adjusted operating margin stalling in the mid-teens and organic bookings growth below low-single-digits → the margin plateau is here, and the secular-compounder thesis breaks.

For the bear case (the stock de-rates):

• Energy/chemical/power capex rolls over; organic growth stalls; the margin plan plateaus in the mid-teens.
• The market re-rates a β-1.4, cost-of-capital-return cyclical from ~17x forward toward its historical low-teens P/E and ~12–13x EV/EBITDA.
• Falsification test: adjusted operating margin marches through 16–17% with mid-single-digit organic bookings growth and adjusted ROIC clearly above 13% for consecutive quarters → the plan is compounding, and the “peak-cyclical” framing is wrong.

15. Source Appendix

See the separate Source Appendix (Appendix B in the combined report) for the full, dated source list. Primary sources: Flowserve FY2025 10-K and press release (8-K, 2026-02-05); Q1-2026 10-Q and earnings call (2026-04-30); the Chart Industries merger 8-Ks/425s (2025-06-04) and termination 8-Ks (2025-07-29); the Trillium Valves 8-K (2026-06-30); the DEF 14A proxy; the 5-year Form 4 corpus; supplemented by ROIC.ai (fundamentals/ratios/EV), AZI (news/valuation percentiles/price history) and FactorsToday (factor positioning).

APPENDIX A — Standard Diligence Questionnaire

Fact / Interpretation / Assumption labeled where it matters.

General

What thoughtful questions have other investors asked about this company? The central debate is quality and durability of the margin turnaround vs. price: is Flowserve a secular self-help compounder (80/20 → ~20% adjusted operating margin by 2030) or a cyclical energy/chemical name enjoying a mid-cycle margin recovery that will plateau? Investors probe (i) how much 80/20 benefit remains; (ii) whether adjusted EPS overstates run-rate earnings given recurring restructuring; (iii) the cyclicality of oil-&-gas/chemical capex; (iv) the nuclear franchise’s real revenue trajectory; and (v) capital-allocation discipline after the abortive Chart merger. The TD Cowen downgrade to Hold ($70 PT, June-2026) crystallized the “fairly valued after the run” view. [Interpretation]

Cyclicality & Earnings Nature

Are earnings at a cyclical high or low? Margins are at a cyclical/structural high and rising (adjusted operating margin mid-teens, targeted ~20% by 2030), but volumes are mid-cycle-to-soft (2026 organic guidance cut to −1/+2% on Middle-East disruption). Earnings are being driven as much by internal self-help (80/20, footprint) as by the external cycle — a genuinely mixed picture, which is the bull’s best argument (margin gains are structural, not just cyclical). [Interpretation] Driven by external environment or internal actions? Both — but the incremental story is internal (the Flowserve Business System). [Interpretation] How stable are revenues? Moderately cyclical: revenue fell/stalled 2020–2022 with the energy trough, then grew ~19% (2023) on recovery. The ~56%-of-bookings aftermarket is the stable annuity; OE is cyclical. [Fact] Outlook for products/services? Favorable long-term (energy security, nuclear, power, decarbonization, aftermarket capture); soft near-term (Middle East, chemical weakness). [Fact/Interpretation] How big is the market — growing/shrinking, domestic/international? Global flow-control TAM is tens of billions (industrial pumps alone ~$70B+), growing low-to-mid-single digits, and heavily international (Americas, EMEA, Asia-Pacific). [Fact]

Business Quality & Competitive Moat

Is the industry getting more or less competitive? Stable — fragmented and competitive in OE, semi-captive in aftermarket; slow consolidation via M&A. [Interpretation] How profitable is the business (ROIC, ROE)? GAAP ROIC ~9.4%, ROE ~7.9% (2025) — roughly cost of capital; adjusted ROIC ~12–13%. Low end of the flow/industrial peer set. [Fact/Interpretation] How profitable is the industry — competitors, barriers? Mixed: low-margin, competitive OE; high-margin, barrier-protected aftermarket (qualification lock-in, downtime cost). Barriers to entry are high in aftermarket/nuclear, moderate in OE. Competitors: ITT/Goulds, Xylem, Sulzer, KSB, Grundfos, John Crane/Smiths, Weir, Emerson, Baker Hughes. [Fact/Interpretation] Can the business be easily understood? Yes — it makes and services pumps, seals, valves. [Fact] Undermined by foreign low-cost labor? Low risk for engineered/mission-critical/aftermarket products (qualification, reliability, service proximity matter more than unit labor cost); some commodity OE is contestable. [Interpretation] Do brands matter? Yes — Flowserve, and specification-by-name in high-consequence applications, carry real weight (reliability track record, spares). [Interpretation] Nature of competition? Project bids (OE) and installed-base capture (aftermarket). [Fact] Customer switching costs? High in aftermarket (re-engineering, requalification, downtime risk); lower in OE. [Interpretation]

Financial Condition & Balance Sheet

Assets not fully recognized on the balance sheet? The installed base (decades of future aftermarket revenue) and the 80/20-driven margin capacity are economic assets not on the books. [Interpretation] Off-balance-sheet liabilities? Legacy asbestos liability was addressed via a Q4-2025 divestiture (a genuine de-risking, at a one-time cost); pension and operating leases are disclosed. Minority interest (~$63M) from JVs. [Fact] How conservative is the accounting? Adequate, but the 38% GAAP-to-adjusted EPS wedge and recurring “one-time” restructuring warrant skepticism of adjusted figures. [Interpretation] How CapEx-hungry? Modestly — capex ~$90–100M/year (~2% of sales); the business is more working-capital-intensive than capex-intensive (2022 saw negative FCF on a working-capital surge). [Fact]

Capital Allocation & Management

How much FCF, and how is it used? ~$400–500M FCF; used for a roughly-flat dividend (~$0.80–0.84/share, ~$105–110M/yr), share buybacks ($254.9M in 2025 — dormant 2022–2023 — largely funded by the $266M Chart break fee; ~$365M total returned in 2025), and bolt-on M&A. [Fact] Significant recent acquisitions? MOGAS Industries (~$306M, 2024, severe-service valves); Greenray Turbine (~$66M, 2025); Trillium Flow Technologies Valves ($490M all-cash, closed June-30-2026 — ~$200M revenue, high-teens EBITDA margin, ~2.45x sales / ~13–14x EBITDA). The Chart Industries all-stock merger of equals (announced June-3-2025) was terminated July-28-2025 when Chart accepted Baker Hughes’ ~$13.6B bid; FLS collected a $266M break fee. [Fact] Buying back shares? Yes — $254.9M repurchased in 2025 (windfall-funded, near the highs); share count drifted down modestly (131M→127M). [Fact] Issuing shares to insiders? SBC is modest (~$38M in 2025, <1% of revenue). Insider Form 4 read (Jan-2025→Jul-2026): 100% distribution — CEO sold ~$15.0M (discretionary, not 10b5-1), CFO ~$3.3M; the only open-market buys were two token director qualifying purchases (~$0.23M combined). Zero officer conviction buying into the re-rating. [Fact] Compensation / motivations of management? Genuinely aligned to the margin/ROIC thesis. Annual bonus: 50% Adjusted Operating Income (margin), 30% Customer Bookings, 20% Adjusted Working Capital. Long-term PSUs: 50% ROIC, 50% FCF conversion, ±15% relative-TSR modifier. CEO Scott Rowe total comp $10.9M (2025); ownership guideline 6× salary; say-on-pay >97%. Caveat: metrics are “adjusted”/non-GAAP and payouts have run hot (192–215% of target). [Fact/Interpretation]

Valuation & Market Data

ADR / MLP / K-1? No — Flowserve is a US-domiciled C-corp common stock (NYSE: FLS); standard 1099 treatment. [Fact] Dividend policy? Roughly flat quarterly dividend (~$0.21/quarter, ~$0.84/year); yield ~1.2%; payout ratio ~28% of GAAP EPS. Not a dividend-growth story. [Fact] How profitable? Improving — mid-teens adjusted operating margin, ~9–13% ROIC. [Fact] Is net income diverging from cash from operations? CFO ($506M) exceeds GAAP net income ($346M) — cash conversion is healthy (>1.4x), aided by D&A and the non-cash asbestos charge; but 2022 showed CFO can invert on working capital. [Fact]

Risks & Downside

What would cause the stock to decline? An energy/chemical capex downturn; a margin-plan plateau; escalation of the Middle-East disruption; a multiple de-rating of a β-1.4 name at ~17x forward; or a value-destructive large acquisition. [Interpretation] Risk of catastrophic loss? Low — diversified, cash-generative, net leverage ~1.2x, credit-facility recently extended. [Fact] Chance of total loss? Very low — no going-concern or single-point-of-failure risk. [Interpretation]

Recent News & Events

Has the business environment changed recently? Yes — (i) the 2025–2026 Middle-East conflict disrupted Q1-2026 bookings (~$50M) and sales (~200bp), with two-sided medium-term rebuild optionality; (ii) the Trillium Valves acquisition ($490M, 2026); (iii) the abortive Chart Industries merger of equals (announced June-2025, terminated July-2025); (iv) the Q4-2025 asbestos divestiture; (v) newly-set 2030 financial targets (Feb-2026); (vi) an FPD leadership change (Matt Copper, March-2026). [Merger/insider specifics pending fact pack.] [Fact] Change in accounting policies? None material identified. [Interpretation] Recent changes — new markets, facilities, management? Ongoing footprint/roofline consolidation (fewer facilities); expanding nuclear franchise; FPD division leadership change. [Fact]

APPENDIX B — Source Appendix

Source Appendix — Flowserve Corporation (NYSE: FLS)

Report date: 2026-07-11. Primary sources first; third-party/aggregated data labeled. All financial figures reconciled to Flowserve’s SEC filings where possible.

Primary — Flowserve SEC filings (EDGAR, CIK 0000030625)

• FY2025 Form 10-K (filed 2026-02-17) — business description, segments, end markets, risk factors, full financial statements. Mirrored: output/FLS/sources/10-K/2026-02-17_fls-20251231.htm.
• FY2024 / FY2023 / FY2022 / FY2021 Form 10-K (2025-02-26 / 2024-02-20 / 2023-03-07 / 2022-02-23) — 5-year trend, capital allocation, dividend/buyback history, M&A.
• Q1-2026 Form 10-Q (filed 2026-04-29) — latest quarter statements, segment detail, leverage.
• FY2025 earnings press release — 8-K exhibit 99.1, filed 2026-02-05 (https://www.sec.gov/Archives/edgar/data/30625/000119312526039379/d42935dex991.htm): full-year and Q4 results, adjusted EPS $3.64, bookings $4,713.0M, aftermarket $2,644.5M, backlog $2,867.8M, 2026 guidance ($4.00–4.20 adj EPS), 2030 targets, Trillium announcement.
• Chart Industries merger 8-K (filed 2025-06-04) and related Form 425 merger communications (10 filings) — merger-of-equals announcement and terms.
• Chart merger termination 8-Ks (filed 2025-07-29, two filings) — termination of the merger of equals.
• Trillium Flow Technologies Valves acquisition 8-K (filed 2026-06-30) — $490M bolt-on.
• DEF 14A proxy statements (2022–2026) — executive compensation, incentive metrics, ownership, board.
• Form 3/4/4A insider-transaction corpus (235 Form 4 + 18 Form 4/A + 10 Form 3) and recent Form 144s (June 2026) — insider buying/selling read.
• 5-year SEC corpus mirrored locally to output/FLS/sources/ (git-ignored).

Primary — Management commentary (hypothesis, validated against filings)

• Flowserve Q1-2026 earnings call transcript (2026-04-30), CEO Scott (Robert) Rowe, CFO Amy Schwetz — via ROIC.ai. Margin cadence, Middle-East disruption, nuclear, 80/20, guidance, capital allocation.

Third-party / aggregated data (reconciled to filings; not primary)

• ROIC.ai MCP — income statement, balance sheet, cash flow, profitability/credit/liquidity ratios, per-share data, enterprise value, valuation multiples (annual, 2020–2025). Pulled 2026-07-11.
• AZI (azitrading.com) — news feed; valuation_index own-history percentiles (P/E 47.5th, P/S 94.5th, composite 79th; P/B percentile disregarded as garbled — see memo Section 6 data note); 5-year adjusted/unadjusted price CSV. Data as of 2026-07-10.
• FactorsToday — factor loadings, leaderboard (risk-adjusted returns by horizon), stock-info (beta 1.44, relative strength), related/factor-similar stocks. Data as of 2026-07-10.

Peer / cross-read (prior published peer analysis)

• ITT (2026-07-11), IDEX (2026-07-11), Xylem (2026-06-27), Pentair (2026-07-10), Dover (2026-07-03), Graco (2026-07-10), A.O. Smith (2026-06-08) — flow-control / diversified-industrial peer returns, moats and valuation framing.

Key reconciled figures (as used in the memo)

• Price $70.48 (2026-07-10); market cap ~$8.9–9.0B; EV ~$10.1B; shares ~127M.
• FY2025: revenue $4,729.3M; GAAP op margin 11.0%; gross margin 33.4%; GAAP diluted EPS $2.64; adjusted EPS $3.64; EBITDA $615M; CFO $506M; ROIC 9.4%; ROE 7.9%.
• Balance sheet: cash $760M; total debt $1.76B; net debt $815M; net leverage ~1.2–1.3x; book value/sh $34.48; tangible book/sh $5.11.
• Valuation: P/E 27x GAAP / 19x adj-2025 / 17x fwd adj-2026; EV/EBITDA 16.4x; EV/Sales 2.13x; FCF yield ~4.5%.